DOTA-XYIMSR-01

DOTA-XYIMSR-01 is a molecular probe targeting CAIX, capable of being labeled with 177Lu for the treatment and localization of malignant gliomas. The uptake of [177Lu]Lu-XYIMSR-01 in U87MG tumors is 6.19% injected dose per gram (% ID/g), with a tumor-to-muscle uptake ratio of 20.14. In an orthotopic glioma model, co-administration with temozolomide significantly enhances survival rates and inhibits tumor growth in mice. DOTA-XYIMSR-01 shows potential for research in the field of cancer treatment.

C(CCC(N[C@@H](CC(N[C@@H](CC(N[C@@H](CCCCN1C=C(CCCC(NC=2SC(S(N)(=O)=O)=NN2)=O)N=N1)C(NCCOCCOCCNC(CN3CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC3)=O)=O)=O)C(O)=O)=O)C(O)=O)=O)(C)(C4=CC=C(O)C=C4)C5=CC=C(O)C=C5